← Back to Analyst Consensus 
TCRX Buy
TScan Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Sep 3, 2026 | Wedbush | downgrade | Outperform → Neutral | — | 58% |
| Sep 2, 2026 | Needham | downgrade | Buy → Hold | — | 50% |
| Aug 12, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 23, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jun 23, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Mar 5, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Nov 13, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Nov 4, 2025 | BTIG | downgrade | Buy → Neutral | $0 | 52% |
| Nov 4, 2025 | Needham | maintain | Buy → Buy | $6 | 50% |
| May 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Apr 8, 2025 | Needham | reiterate | Buy → Buy | $9 | 50% |
| Mar 7, 2025 | Barclays | maintain | Overweight → Overweight | $3 | 53% |
| Mar 6, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Mar 5, 2025 | Needham | maintain | Buy → Buy | $9 | 50% |
| Dec 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Dec 11, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Nov 12, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Nov 6, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Aug 13, 2024 | Wedbush | reiterate | Outperform → Outperform | $10 | 58% |
| Aug 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Aug 12, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Jun 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| May 16, 2024 | BTIG | initiate | — → Buy | $12 | 52% |
| May 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| May 13, 2024 | Needham | reiterate | Buy → Buy | $11 | 50% |
| Apr 23, 2024 | Wedbush | reiterate | Outperform → Outperform | $10 | 58% |
| Mar 7, 2024 | Barclays | maintain | Overweight → Overweight | $9 | 53% |
| Mar 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Feb 1, 2024 | Wedbush | reiterate | Outperform → Outperform | $9 | 58% |
| Aug 14, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Jun 22, 2023 | Wedbush | initiate | — → Outperform | $8 | 58% |
| May 18, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| May 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Mar 9, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $15 | 44% |
| May 10, 2022 | HC Wainwright & Co. | maintain | — → Buy | $15 | 44% |
| Dec 16, 2021 | HC Wainwright & Co. | initiate | — → Buy | $21 | 44% |
| Aug 13, 2021 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Aug 10, 2021 | Morgan Stanley | initiate | — → Overweight | $22 | 54% |
| Aug 10, 2021 | Jefferies | initiate | — → Buy | $21 | 52% |
Price Target Trend
Apr 22, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days